• 1
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment–a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:14031419.
  • 2
    Viera AJ. Resistant hypertension. J Am Board Fam Med. 2012;25:487495.
  • 3
    Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907913.
  • 4
    O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:17311767.
  • 5
    Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens. 2009;27:280286.
  • 6
    Franklin SS, Thijs L, Hansen TW, et al. White-coat hypertension: new insights from recent studies. Hypertension. In press.
  • 7
    Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol. 2011;9:8.
  • 8
    O'Brien E. Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J Intern Med. 2011;269:478495.
  • 9
    O'Brien E. Why ABPM should be mandatory in all trials of blood pressure-lowering drugs. Drug Inf J. 2011;45:233239.
  • 10
    O'Brien E. First Thomas Pickering memorial lecture: ambulatory blood pressure measurement is essential for the management of hypertension. J Clin Hypertens (Greenwich). 2012;14:836847.
  • 11
    Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837841.
  • 12
    Schmieder RE, Redon J, Grassi G, et al. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention. 2013;9(suppl R):R58R66.
  • 13
    Frohlich ED. Renal denervation using an irrigated radiofrequency ablation catheter for management of drug-resistant hypertension: a demonstrated value? JACC Cardiovasc Interv. 2012;5:766768.
  • 14
    Hering D, Lambert EA, Marusic P. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457464.
  • 15
    Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132140.
  • 16
    Mearns BM. Hypertension: further EnligHTNment on renal sympathetic denervation. Nat Rev Cardiol. 2013;10:490.
  • 17
    Parati G, Ochoa JE, Bilo G. Renal sympathetic denervation and daily life blood pressure in resistant hypertension: simplicity or complexity? Circulation. 2013;128:315317.
  • 18
    Pathak A, Girerd X, Azizi M, et al. Expert consensus: renal denervation for the treatment of arterial hypertension. Arch Cardiovasc. Dis. 2012;7:386393.
  • 19
    Persu A, Renkin J, Asayama K, et al. Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence. Expert Rev Cardiovasc Ther. 2013;11:739749.
  • 20
    Alnima T, de Leeuw PW, Kroon AA. Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract. 2012;2012:587194.
  • 21
    Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension. 2011;57:880886.
  • 22
    Scheffers IJM, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present, and future. Curr Hypertens Rep. 2010;12:6166.
  • 23
    Uppuluri SC, Storozynsky E, Bisognano JD. Baroflex device therapy in the treatment of hypertension. Curr Hypertens Rep. 2009;11:6975.
  • 24
    Korsheed S, Eldehni MT, John SG, et al. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant. 2011;26:32963302.
  • 25
    Brouwers S, Dolan E, Galvin J, et al. Creation of an iliofemoral arteriovenous fistula in patients with severe hypertension: a prospective open label multi-center pilot study. J Hypertens. 2013;31(e-suppl A):e103.
  • 26
    Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012;30:874876.
  • 27
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:12751281.
  • 28
    Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:19031909.
  • 29
    Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559565.
  • 30
    Zuern CS, Rizas KD, Eick C, et al. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol 2012;3:134.
  • 31
    Kiuchi MG, Maia GL, de Queiroz Carreira MA, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34:21142121.
  • 32
    Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:21322140.
  • 33
    Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatments: a meta-analysis. J Hypertens. 2004;22:435445.
  • 34
    Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinical and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824830.
  • 35
    Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60:310318.
  • 36
    Wang JG, Sun NL, Ke YN, et al. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements. Clin Drug Invest. 2012;32:729734.
  • 37
    Schmieder RE, Ruilope LM, Ott C, et al. Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. J Hum Hypertens. 2013May 2: doi: 10.1038/jhh.2013.39 [Epub ahead of print].
  • 38
    Mancia G, Parati G, Bilo G, et al. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension. 2012;60:14001406.
  • 39
    Martin EA, Victor RG. Premise, promise, and potential limitations of invasive devices to treat hypertension. Curr Cardiol Rep. 2011;13:8692.
  • 40
    Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension; results of a European multicenter feasibility study. J Am Coll Cardiol. 2010;56:12541258.
  • 41
    Persu A, Jin Y, Azizi M, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2013. In press.
  • 42
    Verloop WL, Vink EE, Voskuil M, et al. Eligibility for percutaneous renal denervation: the importance of a systematic screening. Hypertens. 2013;31:16621668.
  • 43
    O'Brien E, Turner JR. Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2013;15:5562.
  • 44
    Howren MB. Adherence. In: Gellman MD, Turner JR, eds. Encyclopedia of Behavioral Medicine. New York: Springer; 2013:3339.
  • 45
    Turner JR. Patient and physician adherence in hypertension management. J Clin Hypertens (Greenwich). 2013;15:447452.
  • 46
    Hill MN, Miller NH, DeGeest S. ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12:757764.
  • 47
    Waeber B, Feihl F. Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy. EuroIntervention. 2013;9(suppl R):R29R34.
  • 48
    Parati G, Omboni S, Compare A, et al. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs conventional management and assessment of psychological determinants of adherence (TELEBPMET Study). Trials 2013;14:22.
  • 49
    Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62:218225.
  • 50
    Fadl Elmula EF, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526532.
  • 51
    Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis J Hypertens. 2013;31:766774.
  • 52
    Elliott WJ. High prevalence of white-coat hypertension in Spanish resistant hypertensive patients. Hypertension. 2011;57:889890.
  • 53
    Moser M, Setaro JF. Refractory or difficult-to-control hypertension. N Engl J Med. 2006;355:385392.
  • 54
    Ott C, Mahfoud F, Schmid A, et al. Renal denervation in moderate treatment resistant hypertension. J Am Coll Cardiol. 2013 Jun 27: doi: 10.1016/j.jacc.2013.06.023 [Epub ahead of print].
  • 55
    Böhm M, Linz D, Urban D, et al. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol. 2013;10:465476.